SCM
DMAC icon

Sterling Capital Management’s DiaMedica Therapeutics DMAC Stock Holding History

Sterling Capital Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$908 Sell
129
-77
-37% -$473 ﹤0.01% 3149
2026
Q1 		$1.4K Hold
206
– – ﹤0.01% 3046
2025
Q4 		$1.64K Buy
206
+129
+168% +$965 ﹤0.01% 3089
2025
Q3 		$529 Buy
77
+13
+20% +$71 ﹤0.01% 3151
2025
Q2 		$250 Buy
+64
New +$250 ﹤0.01% 3221

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Sterling Capital Management's DMAC Position: Q2 2026 in Review

Sterling Capital Management reduced its DiaMedica Therapeutics (DMAC) stake by 37% in Q2 2026, selling an estimated $473 and leaving 129 shares worth $908. The position accounts for ﹤0.01% of the portfolio, ranked #3149.

Sterling Capital Management first reported a position in DMAC in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.64K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Sterling Capital Management held 129 shares of DiaMedica Therapeutics worth $908 as of Q2 2026.
  • Sterling Capital Management sold 77 DiaMedica Therapeutics shares in Q2 2026, an estimated $473.
  • DiaMedica Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3149 holding.
  • Sterling Capital Management first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's DiaMedica Therapeutics position peaked at $1.64K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.